Delphi Genetics

Solution provided
Supplier identity
General description

Delphi Genetics was founded in November 2001. It is a spin-off company of the University of Brussels located in Gosselies, Belgium. Delphi Genetics is active in the field of molecular biology and more precisely in bioproductions (proteins, DNA). The company develops technolgogies to produce recombinant proteins and DNA with higher yields and without antibiotic resistance genes. Delphi Genetics is also providing several services as gene synthesis, protein production, antibody development...

Type of Supplier
Biotechnology Company - TherapeuticsBioprocess Solutions Provider
Sector of activity
  • Biomanufacturing
  • Drug Discovery / Research & Development
  • Gene / Cell Therapy
  • In vitro Diagnostics
  • Molecular biology
Region of Wallonia, BE
Regional access broker
  • Annick Pierrard, Interface Enterprises-University of Liège
Activity description
Terms of availability for SMEs

Delphi Genetics has developed the Staby® technology to replace antibiotic-resistance genes by a selection system that uses two natural bacterial genes (see below).
Delphi Genetics is also providing several services to industries and academic laboratories based on its technologies or only on the know-how of its researchers:
-Gene synthesis
-Sequence optimization for protein production
-DNA cloning and mutagenesis
-plasmid stabilization without antibiotics (Staby® technology)
-plasmid DNA production (non-GMP)
-Customized protein production (non-GMP)
-In-house genome sequencing and analysis
-Q-PCR analysis
-Customized strain adaptations
-Polyclonal and Monoclonal antibody development based on unique technology for difficult-to-produce antigens

Delphi Genetics is ISO9001:2008 certified, demonstrating the high standards of quality in providing customer services and technologies.

The Staby® technology
The Staby technology is consistent with the recommendations of the FDA and EMA with regard to elimination of Antibiotic Resistance Genes in protein production processes for both human and veterinary uses. The Staby® technology is already used successfully for production of recombinant proteins in E. coli to achieve higher yields and using antibiotics-free media. The technology is licensed to Sanofi-Pasteur and GSK for production of human recombinant proteins used as vaccines. Delphi Genetics is now developing the application of the technology to the field of DNA vaccines in order to avoid completely the use of antibiotics resistance genes from DNA cloning to DNA production. Other research projects are under way to adapt the technology to mammalian cells and yeast.

For more information, please, see our website ( ) or send us an email to delphigenetics(at)

Quality labels and accreditations

Delphi Genetics is ISO9001:2008 certified, demonstrating the high standards of quality in providing customer services and technologies.

Training and Staff possibilities
Contact information
Phone number
+32 (0) 71 25 10 00
Rue A. de Saint-Exupéry, 5
6041  Gosselies